CareDx Reports Fourth Quarter and Full Year 2020 Results
CareDx, a precision medicine company, reported strong financial results for Q4 and full-year 2020. Q4 revenue reached $58.6 million, a 64% increase year-over-year, contributing to a record $192.2 million for the full year, up 51% from 2019. The company achieved a non-GAAP net income of $4.3 million in Q4 and $11.3 million for the full year. Despite a GAAP net loss of $3.5 million in Q4, the results signal a positive trajectory. Additionally, CareDx has provided over 79,000 patient results in 2020 and received Medicare reimbursement for AlloSure Heart.
- Q4 revenue increased 64% to $58.6 million.
- Full-year revenue reached $192.2 million, up 51% from 2019.
- Q4 non-GAAP net income was $4.3 million, compared to $1.6 million in Q4 2019.
- Positive adjusted EBITDA of $4.9 million in Q4 2020.
- Improved cash flow with $7.2 million from operating activities in Q4 2020.
- GAAP net loss of $3.5 million in Q4.
- Full-year net loss of $18.7 million, though improved from $22.0 million in 2019.
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the fourth quarter and full year ended December 31, 2020.
Recent Highlights:
- Achieved total revenue of
$58.6 million for the three months ended December 31, 2020, increasing64% over prior year fourth quarter - Delivered record full year revenue of
$192.2 million , an increase of51% compared with full year 2019 revenue - Provided over 25,000 patient results in the fourth quarter and approximately 79,000 patient results in 2020
- Generated GAAP net loss of
$3.5 million , non-GAAP net income of$4.3 million , and positive adjusted EBITDA of$4.9 million in the fourth quarter - As of December 31, 2020, over 55 U.S.-based transplant centers have adopted an AlloSure Kidney testing protocol
- Received Medicare reimbursement pricing for AlloSure Heart
"Our record fourth quarter result was the culmination of an extraordinary year for CareDx," said Reg Seeto, President and Chief Executive Officer of CareDx. "2020 was transformational for CareDx, because we extended our leadership position in transplant centers through RemoTraC, implemented and validated the next wave of innovation through our multi-modality platforms, HeartCare and KidneyCare, and accelerated the direct to patient journey through AlloCare. We look forward to 2021 and beyond as we invest in advancing our robust pipeline and continue our mission to serve transplant patients and improve outcomes."
Fourth Quarter 2020 Financial Results
Revenue for the three months ended December 31, 2020 was
For the fourth quarter of 2020, net loss was
Non-GAAP net income was
Adjusted EBITDA for the fourth quarter of 2020 was a gain of
Net cash provided by operating activities in the fourth quarter of 2020 was
Full Year 2020 Financial Results
Revenue for the full year ended December 31, 2020 was
Net loss for the full year ended December 31, 2020 was
Non-GAAP net income was
For additional information regarding non-GAAP financial measures discussed herein, please see "Use of Non-GAAP Financial Measures," "Reconciliation of GAAP to Non-GAAP Financial Measures" and "Reconciliation of GAAP to Non-GAAP Adjusted EBITDA Financial Measures" below.
2021 Guidance
For the full year 2021, CareDx expects revenue to be in the range of
About CareDx
CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements, including expectations regarding the Company's fiscal 2021 revenue, achievement of our financial and operational goals and our prospects. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including general economic and market factors, among others discussed in CareDx's filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed by CareDx with the SEC on February 28, 2020, and the periodic reports that CareDx has subsequently filed with the SEC. Any of these may cause CareDx's actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
Use of Non-GAAP Financial Measures
CareDx has presented in this release certain financial information in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and also on a non-GAAP basis, including non-GAAP net income, non-GAAP basic and diluted net income per share and adjusted EBITDA. We define non-GAAP net income and per share results as the GAAP net income and per share results excluding the impacts of stock-based compensation; changes in estimated fair value of warrants, derivative liabilities and contingent consideration; acquisition related impairment charges and amortization of intangible assets, purchase accounting adjustments and related tax effects; costs involved with completing an acquisition; amortization of debt discount; and certain other financing charges. We define adjusted EBITDA as non-GAAP net income/(loss) before net interest income/(expense), income tax benefit, depreciation and amortization, and other income and expense. We are presenting these non-GAAP financial measures to assist investors in assessing our operating results through the eyes of management and because we believe that these measures provide an additional tool for investors to use in comparing our core business operating results over multiple periods. Management believes this non-GAAP information is useful for investors, when considered in conjunction with CareDx's GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of CareDx's operating results as reported under GAAP. These non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. These non-GAAP financial measures are not necessarily comparable to similarly-titled measures presented by other companies. A reconciliation between GAAP and non-GAAP financial information is provided immediately following the financial tables.
Investor Relations Contact
Greg Chodaczek
347-620-7010
investor@caredx.com
CareDx, Inc.
Consolidated Statements of Operations
(Unaudited)
(In thousands, except share and per share data)
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
| Revenue: | ||||||||||||||||
| Testing services revenue | $ | 50,346 | $ | 29,129 | $ | 163,610 | $ | 104,550 | ||||||||
| Product revenue | 5,933 | 5,053 | 19,302 | 18,279 | ||||||||||||
| Digital and other revenue | 2,365 | 1,639 | 9,282 | 4,239 | ||||||||||||
| Total revenue | 58,644 | 35,821 | 192,194 | 127,068 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Cost of testing services | 13,301 | 7,694 | 43,932 | 29,622 | ||||||||||||
| Cost of product | 4,212 | 3,758 | 13,847 | 12,919 | ||||||||||||
| Cost of digital and other | 1,372 | 1,264 | 5,338 | 2,914 | ||||||||||||
| Research and development | 13,325 | 8,946 | 48,941 | 30,711 | ||||||||||||
| Sales and marketing | 16,131 | 10,267 | 53,858 | 38,894 | ||||||||||||
| General and administrative | 13,370 | 9,437 | 48,806 | 36,540 | ||||||||||||
| Total operating expenses | 61,711 | 41,366 | 214,722 | 151,600 | ||||||||||||
| Loss from operations | (3,067 | ) | (5,545 | ) | (22,528 | ) | (24,532 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income, net | 125 | 306 | 271 | 985 | ||||||||||||
| Change in estimated fair value of common stock warrant liability | (505 | ) | 333 | (1,495 | ) | 319 | ||||||||||
| CARES Act Provider Relief Fund | — | — | 4,813 | — | ||||||||||||
| Other expense, net | (239 | ) | (75 | ) | (811 | ) | (719 | ) | ||||||||
| Total other income (expense) | (619 | ) | 564 | 2,778 | 585 | |||||||||||
| Loss before income taxes | (3,686 | ) | (4,981 | ) | (19,750 | ) | (23,947 | ) | ||||||||
| Income tax benefit | 171 | 204 | 1,036 | 1,979 | ||||||||||||
| Net loss | $ | (3,515 | ) | $ | (4,777 | ) | $ | (18,714 | ) | $ | (21,968 | ) | ||||
| Net loss per share: | ||||||||||||||||
| Basic | $ | (0.07 | ) | $ | (0.11 | ) | $ | (0.40 | ) | $ | (0.52 | ) | ||||
| Diluted | $ | (0.07 | ) | $ | (0.11 | ) | $ | (0.40 | ) | $ | (0.52 | ) | ||||
| Weighted-average shares used to compute net loss per share: | ||||||||||||||||
| Basic | 49,325,898 | 42,457,171 | 46,481,772 | 42,151,617 | ||||||||||||
| Diluted | 49,325,898 | 42,457,171 | 46,481,772 | 42,151,617 | ||||||||||||
CareDx, Inc.
Consolidated Balance Sheets
(in thousands)
| As of December 31, | ||||||||
| 2020 | 2019 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 134,669 | $ | 38,223 | ||||
| Marketable securities | 90,034 | — | ||||||
| Accounts receivable | 34,624 | 24,057 | ||||||
| Inventory | 10,012 | 6,014 | ||||||
| Prepaid and other current assets | 3,758 | 3,628 | ||||||
| Total current assets | 273,097 | 71,922 | ||||||
| Property and equipment, net | 10,704 | 4,430 | ||||||
| Operating leases right-of-use assets | 15,228 | 4,730 | ||||||
| Intangible assets, net | 44,355 | 45,541 | ||||||
| Goodwill | 23,857 | 23,857 | ||||||
| Restricted cash | 270 | 256 | ||||||
| Other assets | 1,000 | 1,000 | ||||||
| Total assets | $ | 368,511 | $ | 151,736 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 9,653 | $ | 5,506 | ||||
| Accrued compensation | 18,466 | 12,484 | ||||||
| Accrued and other liabilities | 20,602 | 16,838 | ||||||
| Refund liability - CMS advance payment | 20,496 | — | ||||||
| Total current liabilities | 69,217 | 34,828 | ||||||
| Deferred tax liability | 1,299 | 1,973 | ||||||
| Common stock warrant liability | 447 | 6,607 | ||||||
| Deferred payments for intangible assets | 3,560 | 5,207 | ||||||
| Operating lease liability, less current portion | 16,069 | 2,370 | ||||||
| Other liabilities | 240 | 1,751 | ||||||
| Total liabilities | 90,832 | 52,736 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Common stock | 49 | 42 | ||||||
| Additional paid-in capital | 632,253 | 437,976 | ||||||
| Accumulated other comprehensive loss | (2,096 | ) | (5,205 | ) | ||||
| Accumulated deficit | (352,527 | ) | (333,813 | ) | ||||
| Total stockholders' equity | 277,679 | 99,000 | ||||||
| Total liabilities and stockholders' equity | $ | 368,511 | $ | 151,736 | ||||
CareDx, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(Unaudited)
(In thousands)
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
| Cost of testing services reconciliation: | ||||||||||||||||
| GAAP cost of testing services | $ | 13,301 | $ | 7,694 | $ | 43,932 | $ | 29,622 | ||||||||
| Stock-based compensation expense | (392 | ) | (328 | ) | (1,493 | ) | (1,751 | ) | ||||||||
| Acquisition related-amortization of purchased intangibles | (329 | ) | (330 | ) | (1,316 | ) | (738 | ) | ||||||||
| Non-GAAP cost of testing services | $ | 12,580 | $ | 7,036 | $ | 41,123 | $ | 27,133 | ||||||||
| Cost of product reconciliation: | ||||||||||||||||
| GAAP cost of product | $ | 4,212 | $ | 3,758 | $ | 13,847 | $ | 12,919 | ||||||||
| Stock-based compensation expense | (102 | ) | (88 | ) | (391 | ) | (280 | ) | ||||||||
| Acquisition related-amortization of purchased intangibles | (455 | ) | (379 | ) | (1,665 | ) | (1,446 | ) | ||||||||
| Non-GAAP cost of product | $ | 3,655 | $ | 3,291 | $ | 11,791 | $ | 11,193 | ||||||||
| Cost of digital and other reconciliation: | ||||||||||||||||
| GAAP cost of digital and other | $ | 1,372 | $ | 1,264 | $ | 5,338 | $ | 2,914 | ||||||||
| Stock-based compensation expense | (111 | ) | (62 | ) | (449 | ) | (152 | ) | ||||||||
| Acquisition related-amortization of purchased intangibles | (86 | ) | (79 | ) | (345 | ) | (210 | ) | ||||||||
| Non-GAAP cost of digital and other | $ | 1,175 | $ | 1,123 | $ | 4,544 | $ | 2,552 | ||||||||
| Research and development expenses reconciliation: | ||||||||||||||||
| GAAP research and development expenses | $ | 13,325 | $ | 8,946 | $ | 48,941 | $ | 30,711 | ||||||||
| Stock-based compensation expense | (1,186 | ) | (1,196 | ) | (4,676 | ) | (4,422 | ) | ||||||||
| Non-GAAP research and development expenses | $ | 12,139 | $ | 7,750 | $ | 44,265 | $ | 26,289 | ||||||||
| Sales and marketing expenses reconciliation: | ||||||||||||||||
| GAAP sales and marketing expenses | $ | 16,131 | $ | 10,267 | $ | 53,858 | $ | 38,894 | ||||||||
| Stock-based compensation expense | (1,620 | ) | (1,212 | ) | (5,795 | ) | (4,008 | ) | ||||||||
| Acquisition related-amortization of purchased intangibles | (383 | ) | (366 | ) | (1,472 | ) | (1,248 | ) | ||||||||
| Impairment | — | — | — | (150 | ) | |||||||||||
| Non-GAAP sales and marketing expenses | $ | 14,128 | $ | 8,689 | $ | 46,591 | $ | 33,488 | ||||||||
| General and administrative expenses reconciliation: | ||||||||||||||||
| GAAP general and administrative expenses | $ | 13,370 | $ | 9,437 | $ | 48,806 | $ | 36,540 | ||||||||
| Stock-based compensation expense | (2,566 | ) | (2,521 | ) | (10,597 | ) | (11,804 | ) | ||||||||
| Change in estimated fair value of contingent consideration | (8 | ) | (210 | ) | (309 | ) | (210 | ) | ||||||||
| Acquisition related fees and expenses | (115 | ) | — | (115 | ) | (654 | ) | |||||||||
| Non-GAAP general and administrative expenses | $ | 10,681 | $ | 6,706 | $ | 37,785 | $ | 23,872 | ||||||||
| Total other income (expense) reconciliation: | ||||||||||||||||
| GAAP other income (expense), net | $ | (619 | ) | $ | 564 | $ | 2,778 | $ | 585 | |||||||
| Change in estimated fair value of common stock warrant liability | 505 | (333 | ) | 1,495 | (319 | ) | ||||||||||
| Accretion of liability | 80 | 108 | 352 | 281 | ||||||||||||
| Non-GAAP other income (expense), net | $ | (34 | ) | $ | 339 | $ | 4,625 | $ | 547 | |||||||
| Income tax benefit reconciliation: | ||||||||||||||||
| GAAP income tax benefit | $ | 171 | $ | 204 | $ | 1,036 | $ | 1,979 | ||||||||
| Tax effect related to amortization of purchased intangibles | (134 | ) | (129 | ) | (503 | ) | (493 | ) | ||||||||
CareDx, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(Unaudited)
(In thousands, except share and per share data)
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
| GAAP net loss | $ | (3,515 | ) | $ | (4,777 | ) | $ | (18,714 | ) | $ | (21,968 | ) | ||||
| Stock-based compensation expense | 5,977 | 5,407 | 23,401 | 22,417 | ||||||||||||
| Acquisition related-amortization of purchased intangibles | 1,253 | 1,154 | 4,798 | 3,642 | ||||||||||||
| Acquisition related fees and expenses | 115 | — | 115 | 654 | ||||||||||||
| Change in estimated fair value of contingent consideration | 8 | 210 | 309 | 210 | ||||||||||||
| Change in estimated fair value of common stock warrant liability | 505 | (333 | ) | 1,495 | (319 | ) | ||||||||||
| Accretion of liability | 80 | 108 | 352 | 281 | ||||||||||||
| Tax effect related to amortization of purchased intangibles | (134 | ) | (129 | ) | (503 | ) | (493 | ) | ||||||||
| Impairment | — | — | — | 150 | ||||||||||||
| Non-GAAP net income | $ | 4,289 | $ | 1,640 | $ | 11,253 | $ | 4,574 | ||||||||
| GAAP basic and diluted net loss per share | $ | (0.07 | ) | $ | (0.11 | ) | $ | (0.40 | ) | $ | (0.52 | ) | ||||
| Non-GAAP basic net income per share | $ | 0.09 | $ | 0.04 | $ | 0.24 | $ | 0.11 | ||||||||
| Non-GAAP diluted net income per share | $ | 0.08 | $ | 0.04 | $ | 0.23 | $ | 0.10 | ||||||||
| Shares used in computing non-GAAP basic net income per share | 49,325,898 | 42,457,171 | 46,481,772 | 42,151,617 | ||||||||||||
| Shares used in computing non-GAAP diluted net income per share | 52,005,987 | 43,464,685 | 48,274,038 | 44,344,803 | ||||||||||||
CareDx, Inc.
Reconciliation of Non-GAAP to Adjusted EBITDA Financial Measures
(Unaudited)
(In thousands)
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
| Non-GAAP net income | $ | 4,289 | $ | 1,640 | $ | 11,253 | $ | 4,574 | ||||||||
| Interest income | (125 | ) | (306 | ) | (271 | ) | (985 | ) | ||||||||
| Income tax benefit | (37 | ) | (75 | ) | (533 | ) | (1,486 | ) | ||||||||
| Depreciation expense | 632 | 424 | 1,867 | 1,623 | ||||||||||||
| CARES Act Provider Relief Fund | — | — | (4,813 | ) | — | |||||||||||
| Other expense (income), net | 159 | (206 | ) | 459 | 438 | |||||||||||
| Adjusted EBITDA | $ | 4,918 | $ | 1,477 | $ | 7,962 | $ | 4,164 | ||||||||
FAQ
What were CareDx's financial results for Q4 2020?
What is CareDx's revenue guidance for 2021?
How much non-GAAP net income did CareDx report for Q4 2020?
What was the full-year revenue for CareDx in 2020?
Did CareDx receive Medicare reimbursement for any products?
